|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Matrix metalloproteinase 9 (MMP-9) and interleukin-8 (IL-8) play major roles in tumor progression and invasion of breast cancer cells.
|
23933110 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
From our in vitro and in vivo data we suggest that anoxia-induced regulation of IL-8 might be a characteristic feature of aggressive tumor cells, thus indicating that IL-8 might play a critical role for tumor progression in human malignant melanoma.
|
10487833 |
1999 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we investigated the contribution of a related chemokine, CXCL8, to cellular properties associated with tumor progression, namely cell growth and motility.
|
18282785 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCL8-CXCR1/2 axis may play an important role in tumor progression and metastasis by regulating cancer stem cell (CSC) proliferation and self-renewal.
|
28529637 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, interleukin-8 secretion was assessed using ELISA, due to its role in tumor progression and angiogenesis.
|
29436675 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results imply that the complex roles of IL-8 in the regulation of ER-negative breast cancer progression may in part be related to its potent chemotactic effects on neutrophils, which in turn mediates many of the biological functions of IL-8.
|
17621625 |
2007 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells.
|
31488216 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, because of the roles that IL-8 plays in favoring tumor progression, several therapeutic strategies are being developed to interfere with its functions.
|
28866366 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Since IL-8 promotes neutrophil chemotaxis and degranulation during inflammatory responses, and exerts mitogenic and angiogenic actions within tumor microenvironment, our results imply that myeloid RUNX3 expression regulates the recruitment of leukocytes towards inflammatory foci and might also contribute to human cancer progression.
|
20615577 |
2011 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In human TC samples, IL-8 expression is associated with tumor progression.
|
28415590 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additional subsets of CTCs within individual patients were characterized by divergent expression of genes involved in epithelial-mesenchymal transition (e.g., CDH2, MMPs, VIM, or ZEB1 and 2), DNA repair (RAD51), resistance to cancer therapy (e.g., AR, AR-V7, ERBB2, EGFR), cancer stemness (e.g., CD24 and CD44), activated signaling pathways involved in tumor progression (e.g., PIK3CA and MTOR) or cross talks between tumors and immune cells (e.g., CCL4, CXCL2, CXCL9, IL15, IL1B, or IL8).
|
27630154 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chemokine (C-X-C motif) ligand 8 (CXCL8) is involved in acute inflammation and tumor progression through the phosphoinositide-3-kinase/protein kinase B/nuclear factor-κB (PI3K/Akt/NF-κB)-signaling pathway.
|
30362547 |
2019 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, the expression of IL-6 or IL-8 in tumour tissues was validated by immunohistochemistry to be positively correlated with tumour progression and poor survival, respectively.
|
31324197 |
2019 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, in NSCLC, IL-8 mRNA expression is strongly associated with tumor progression, tumor angiogenesis, survival, and time to relapse, suggesting its use as a prognostic indicator.
|
11069840 |
2000 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We performed a gene profiling study by analysing PRAME shRNA-silenced leukemic cells on high-density micro-arrays (Affymetrix) and found that PRAME altered the expression of two additional genes potentially involved in cancerogenesis and cancer progression: IL-8 and IGFBP-2.
|
18452107 |
2008 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Importantly, IL-8 mRNA expression was higher in UC and UCCP patients homozygous for the OCTN1 1672T variant compared to the other genotypes.
|
21793125 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
One functional consequence is increased synthesis of the secreted chemokine interleukin 8, which contributes to metastasis, inflammation, and cancer progression in mice and humans.
|
30842218 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our study proved that CXCL8 acted as an unfavorable factor promoting to tumor progression and poor prognosis of ADC, while DACH1 antagonized CXCL8 to provide a favorable survival of ADC patients.
|
29636079 |
2018 |
|
Tumor Progression
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Our data demonstrated that low tumor pH contributes to the enhanced expression of IL-8 and plays an important role in tumor progression.
|
11096460 |
2000 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These results demonstrate for the first time that IL-8 expression, as detected by in situ hybridization in primary tumours, may serve as a significant prognostic factor for tumour progression in human malignant melanoma.
|
10629556 |
1999 |
|
Tumor Progression
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
These results suggest that SNP in the promoter region of MMP-1 and IL-8 plays an important role in tumor progression and recurrence through its expression in tongue SCC.
|
18276095 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interleukin-8 (IL-8), a potent chemoattractant, has been demonstrated to contribute to human cancer progression through its potential functions as a mitogenic, angiogenic, and motogenic factor.
|
16698420 |
2006 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
<b>Background:</b> Using a secondary data analysis from randomized controlled trials comparing one year of resistance exercise (<i>n</i> = 109) to a placebo control condition (<i>n</i> = 106) in postmenopausal, posttreatment breast cancer survivors, we investigated the influence of resistance training and changes in body composition on markers associated with cancer progression.<b>Methods:</b> Measures included serum levels of insulin, IGF-1, IGFBP1-3, leptin, serum amyloid A (SAA), adiponectin, C-reactive protein (CRP), IL1β, TNFα, IL6, and IL8, and body composition (total, lean and fat mass in kg) by DXA at baseline, 6, and 12 months.
|
29141853 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The overexpression of interleukin-8 (IL-8) is closely associated with poor tumor differentiation, metastasis and tumor progression.
|
27878250 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Western blot analysis showed the ability of SKI-606 to significantly decrease the phosphorylation of signaling molecules (AKT, mitogen-activated protein kinase, focal adhesion kinase) and the expression of tumor progression-associated genes uPAR, MMP-2, MMP-9, N-cadherin, fibronectin, BMP-2 (bone morphogenetic protein 2), BMP-6 (bone morphogenetic protein 6), IL-8 (interleukin 8), and TGF-beta (transforming growth factor beta) in prostate cancer cells.
|
20423991 |
2010 |